Published in Prog Cardiovasc Dis on March 26, 1982
Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol (2009) 0.99
Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress. Br Heart J (1987) 0.90
Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol. Br Heart J (1983) 0.84
Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure. Br Heart J (1986) 0.81
Acute and chronic effects of captopril therapy in patients with refractory heart failure. Br J Clin Pharmacol (1982) 0.75
Vasodilators. Can Med Assoc J (1983) 0.75
Long-term captopril therapy in severe refractory congestive heart failure. Br J Clin Pharmacol (1982) 0.75
The role of digitalis in the future. Br J Clin Pharmacol (1984) 0.75
Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med (1991) 6.16
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 3.14
Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation (1986) 2.69
Ultrasequencing of the meiofaunal biosphere: practice, pitfalls and promises. Mol Ecol (2010) 2.64
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 2.49
Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 2.35
The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg (1999) 2.26
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation (1994) 2.05
Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med (1986) 1.79
Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med (1987) 1.71
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation (1994) 1.67
Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation (1985) 1.65
Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol (1995) 1.63
Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. J Am Coll Cardiol (1989) 1.61
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J (2000) 1.55
Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol (1989) 1.52
Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation (1995) 1.49
Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med (1984) 1.49
Age- and species-specific duration of infection in asymptomatic malaria infections in Papua New Guinea. Parasitology (2000) 1.46
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J (2001) 1.46
A prospective multicenter clinical trial to evaluate the safety and effectiveness of the implantable miniature telescope. Am J Ophthalmol (2004) 1.44
Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation. Ann Thorac Surg (1994) 1.40
Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure. Circulation (1990) 1.39
Deleterious effects of hydralazine in patients with pulmonary hypertension. N Engl J Med (1982) 1.38
Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation (1996) 1.38
Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation (1979) 1.35
Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation (1983) 1.33
Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med (1987) 1.31
Use of power modulations in phacoemulsification. Choo-choo chop and flip phacoemulsification. J Cataract Refract Surg (2001) 1.24
Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol (1994) 1.24
Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure. Circulation (1985) 1.22
End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? N Engl J Med (1997) 1.21
Indications for left ventricular aneurysmectomy. Circulation (1983) 1.20
Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol (1990) 1.15
Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris. Am J Cardiol (1982) 1.14
Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation (1987) 1.11
Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. Am Heart J (1987) 1.10
Do vasodilators prolong life in heart failure? N Engl J Med (1987) 1.09
How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. J Am Coll Cardiol (1987) 1.08
Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J (1986) 1.07
Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 1.07
Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. Circulation (2000) 1.06
Association of human DEAD box protein DDX1 with a cleavage stimulation factor involved in 3'-end processing of pre-MRNA. Mol Biol Cell (2001) 1.05
Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol (1996) 1.04
Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J Am Coll Cardiol (1983) 1.04
Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective. Am J Cardiol (1982) 1.03
Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study. J Am Coll Cardiol (1993) 1.02
Hemodynamic characterization of tolerance to long-term hydralazine therapy in severe chronic heart failure. N Engl J Med (1982) 1.02
Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail (1997) 1.02
The search for the ideal positive inotropic agent. N Engl J Med (1993) 1.02
Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation (1983) 1.02
Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med (1984) 1.01
The role of vasodilator therapy in the treatment of severe chronic heart failure. Drugs (1986) 1.01
Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol (1984) 1.00
Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines. J Biol Chem (1998) 1.00
Regulation of brain fatty acid-binding protein expression by differential phosphorylation of nuclear factor I in malignant glioma cell lines. J Biol Chem (2000) 1.00
Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol (1986) 1.00
Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation (1995) 1.00
Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation (1984) 1.00
Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation (1986) 0.99
Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. Ann Intern Med (1985) 0.96
Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol (1993) 0.96
Activation of neurohumoral systems in postinfarction left ventricular dysfunction. J Am Coll Cardiol (1993) 0.95
Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. Arch Intern Med (2001) 0.94
Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation (1982) 0.94
Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol (1997) 0.93
Sarcoplasmic reticulum calcium transport and Ca(2+)-ATPase gene expression in thoracic and abdominal aortas of normotensive and spontaneously hypertensive rats. J Biol Chem (1993) 0.93
Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with congestive heart failure. Am J Med (1987) 0.92
Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation (1985) 0.92
Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure. J Cardiovasc Pharmacol (1988) 0.91
Sudden death in heart failure: vascular or electrical? Eur J Heart Fail (1999) 0.91
Clinical relevance of verapamil plasma levels in stable angina pectoris. Am J Cardiol (1982) 0.90
Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol (1987) 0.90
Non diethylstilbesterol induced vaginal adenosis--a case series and review of literature. Eur J Gynaecol Oncol (2001) 0.90
Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J (1996) 0.89
Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs. Am Heart J (1982) 0.89
Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol (1984) 0.88
Rebound hemodynamic events after the abrupt withdrawal of nitroprusside in patients with severe chronic heart failure. N Engl J Med (1979) 0.88
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 0.88
Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy. Circulation (1990) 0.86
Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure. Ann Intern Med (1986) 0.86
Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol (1993) 0.85
Coronary endothelial dysfunction precedes heart failure and reduction of coronary reserve in awake dogs. J Mol Cell Cardiol (1997) 0.85
Physical training alters the pathogenesis of pacing-induced heart failure through endothelium-mediated mechanisms in awake dogs. Circulation (1997) 0.85
Calcium antagonists for congestive heart failure: evolving concepts in bridge building. Cardiovasc Drugs Ther (1993) 0.85
Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol (1983) 0.84
Dose requirements of hydralazine in patients with severe chronic congestive heart failure. Am J Cardiol (1980) 0.84
Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy. Circulation (1981) 0.84
Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. N Engl J Med (1980) 0.84
What causes tolerance to nitroglycerin? The 100 year old mystery continues. J Am Coll Cardiol (1990) 0.84
Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther (1996) 0.84
Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol (2001) 0.83
Long-term effectiveness of verapamil in stable and unstable angina pectoris. One-year follow-up of patients treated in placebo-controlled double-blind randomized clinical trials. Am J Cardiol (1982) 0.83
Coupling factor activity of the purified pea mitochondrial F1-ATPase. Biochim Biophys Acta (1985) 0.83
Method for evaluating patient anxiety and the interpersonal effectiveness of dental personnel: an exploratory study. J Dent Res (1971) 0.83